NCT02496208 2026-04-13Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsNational Cancer Institute (NCI)Phase 1 Active not recruiting152 enrolled
NCT03816345 2026-04-13Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVONational Cancer Institute (NCI)Phase 1 Recruiting300 enrolled
NCT05249114 2026-04-13Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine TumorsProvidence Health & ServicesPhase 1 Active not recruiting6 enrolled
NCT03798626 2026-04-01Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal CancersNovartisPhase 1 Completed167 enrolled
NCT04514484 2026-03-23Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVNational Cancer Institute (NCI)Phase 1 Active not recruiting8 enrolled